| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5833672 | International Immunopharmacology | 2011 | 5 Pages |
Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces beneficial therapeutic responses in children and adults. IVIG is not only used for prophylaxis and therapy of infections in patients with primary and secondary immunodeficiencies associated with defective antibody production, but also used for treatment of patients with systemic inflammatory disorders, autoimmune diseases, and neuroimmunologic conditions. IVIG is generally considered a safe and efficacious therapeutic modality. However, it is associated with certain adverse effects including hematologic complications such as hemolytic anemia, leukopenia, neutropenia, monocytopenia, disseminated intravascular coagulation, and changes in blood rheology. Venous and arterial thrombotic complications can also occur following treatment with IVIG in high risk patients. It is very important for clinicians to have the knowledge of those adverse events profiles; and this article summarizes hematologic toxicities associated with IVIG therapy reported in the literature; and describes strategies for their identification and management.
⺠IVIG is generally considered a safe and efficacious therapeutic modality. ⺠IVIG is associated with certain adverse effects including hematologic toxicities. ⺠Hemolytic anemia, leukopenia, neutropenia, monocytopenia, thrombotic complications can occur following treatment with IVIG. ⺠Careful monitoring and appropriate administration techniques will lead to earlier detection and improved clinical outcomes.
